Making cancer drugs better

April 3, 2014 by Anne Trafton
Professor Stephen Lippard delivers the 2014 Killian Lecture at MIT Credit: Dominick Reuter

More than half of all cancer patients who receive chemotherapy are treated with drugs containing platinum. These drugs are very powerful, but like many other chemotherapy agents, they can have side effects and may provoke resistance in tumor cells.

Although platinum-based drugs have been used since the late 1970s, it has taken scientists decades to fully understand how they work. "It's a very simple question but it has a complicated answer," Stephen Lippard, the Arthur Amos Noyes Professor of Chemistry at MIT, said during yesterday's James R. Killian Jr. Faculty Achievement Award Lecture.

For his contributions to unraveling the mechanism of how platinum drugs kill cancer cells, Lippard, one of the founders of the field of bioinorganic chemistry, was awarded this year's Killian Award. "His groundbreaking work has pushed back the frontiers of inorganic chemistry, while simultaneously paving the way for improvements in human health and the conquering of disease," reads the award citation.

"It's a great honor for me to be here," Lippard said after receiving the award from Steven Hall, chair of the MIT faculty and a professor of aeronautics and astronautics. "It's very humbling to be selected by one's peers for this honor."

Powerful drugs

When Lippard began his scientific career in the 1960s, the biological activity of the first platinum drug, cisplatin, had just been identified. The discovery was serendipitous: Michigan State chemist Barnett Rosenberg was investigating the effects of electric fields on the growth of E. coli bacteria, which stopped dividing and grew into long filaments. He eventually realized that platinum leaching from the electrodes used in the experiment was reacting with ammonium chloride in the bacteria's environment to produce cisplatin, which induced the filamentous growth without the electric field.

Subsequently Rosenberg showed that cisplatin could shrink tumors in mice, and the National Cancer Institute began running clinical trials; the Food and Drug Administration approved the drug for treatment of cancer in 1978. Since then, two related platinum drugs, carboplatin and oxaliplatin, have also been approved to treat cancer.

Cisplatin, the simplest of the three, consists of an atom of platinum bound to two molecules of ammonia and two chloride ions. In carboplatin, the two chloride ions are replaced by a more complicated structure, a cyclobutane dicarboxylate. Oxaliplatin has an even more complex architecture, with the central platinum atom bound to two separate ring structures.

After receiving his PhD from MIT in 1965, Lippard joined the faculty at Columbia University and began investigating how these drugs worked, with a focus on their impact on DNA. He continued this pursuit after returning to MIT in 1983, eventually building up evidence that platinum drugs bind to DNA at specific locations, forming cross-links. These linkages prevent the cell from transcribing the genes necessary to initiate cell division, so the cells become unable to divide and undergo programmed cell death, or apoptosis.

"From that understanding, our ultimate goal was to see if we could make improved drug candidates," said Lippard, who is a member of MIT's Koch Institute for Integrative Cancer Research.

New modes of attack

Although platinum drugs have been used successfully to treat many types of cancer—especially testicular cancer—they also have limitations: The drugs can have significant side effects, and cancer cells can become resistant to them, allowing tumors to recur. "That has led us, and others around the world, to look at nonclassical platinum compounds," Lippard said.

In one approach Lippard described, he and others are modifying cisplatin by adding two more chemical groups that have their own anti-cancer activity. After entering a cancer cell, the two components are released, generating cisplatin in the process, and together they attack the cell on multiple fronts. In one early example, Lippard attached cisplatin to a drug known as DCA, which interferes with cancer cell metabolism, forcing them to undergo apoptosis.

Although the DCA-platinum compound proved powerful against cancer cells, Lippard said he doesn't believe it will be developed as a cancer drug. However, this work demonstrated that such an approach is viable: "It shows that we can alter two different types of processes in cancer cells, which I think would make it much more difficult for them to become resistant and hopefully would lead to clinical success," he said.

He also described efforts to package cisplatin into targeted nanoparticles, which could help minimize the drug's side effects and also deliver it directly to cancer cells. He is one of the founders of a company called Blend Therapeutics that is developing this and other approaches to treat cancer.

Another way to improve platinum drugs, Lippard said, is to replace one chloride ion with a large chemical group to form a complex that impedes the transcription of DNA in tumors but without forming cross-links. Earlier research had suggested that neutral platinum compounds with two DNA-binding sites that form cross-links are required to kill cancer cells, but more recent studies have shown that some positively charged "monofunctional" platinum compounds with only one DNA-binding site also have anti-cancer activity.

In a study published in 2012, Lippard showed that a compound called phenanthriplatin, in which one chloride ion is replaced by a bulky three-ring structure, was four to 40 times more potent than in a screen of many types of . The next step is to test the compound's effectiveness in animals, he said, which, with additional improvements, may lead to a clinical trial.

"We're pretty excited about it and we think that phenanthriplatin and compounds like it could be developed and go forward," Lippard said. "I would like to cure at least one person of cancer before I leave the planet."

Explore further: New drug candidate shows promise against cancer

Related Stories

New drug candidate shows promise against cancer

July 11, 2012
Drugs containing platinum are among the most powerful and widely used cancer drugs. However, such drugs have toxic side effects, and cancer cells can eventually become resistant to them.

Resistance is futile: Researchers identify gene that mediates cisplatin resistance in ovarian cancer

April 15, 2013
Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but ...

New ruthenium-based drugs show promise for killing cancer cells

June 11, 2012
A new study by University of Kentucky researchers shows how light and strained ruthenium-based drugs may be more effective at fighting cancer cells and less toxic to healthy cells than a similar and widely used drug.

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.